{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:53:54Z","timestamp":1791298434845,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["T32 MH079785"],"award-info":[{"award-number":["T32 MH079785"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"name":"School of Medicine\/Center for Neurovirology and Gene Editing internal PI fund","award":["161664-04400-02"],"award-info":[{"award-number":["161664-04400-02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CRISPR technology is emerging as a promising therapeutic approach for eliminating chronic viral infections, such as herpesviruses and HIV.\u00a0Here, for the first time, we demonstrate in vitro that CRISPR can be used to excise the HTLV-1 genome and reduce proviral loads in PBMCs from HAM\/TSP (HTLV-1-associated myelopathy\/tropical spastic paraparesis) patients. Single treatment with CRISPR-RNP (ribonucleoprotein) complexes composed of two gRNAs targeting the HTLV-1 env gene and 3\u2019LTR sequences resulted in excision of a 2613\u00a0bp segment of the proviral genome, spanning tax and HBZ genes, without detectable off-target activity. Furthermore, CRISPR treatment led to over 50% reduction in proviral loads 5\u00a0days post-electroporation. Our data indicate that CRISPR-Cas9 gene editing can be used as a therapeutic strategy to eliminate HTLV-1 DNA from infected cells and may serve as a platform for curing HAM\/TSP.<\/jats:p>","DOI":"10.1007\/s13365-026-01333-7","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:48:57Z","timestamp":1788011337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRISPR-mediated excision of HTLV-1 reduces proviral loads in PBMCs from HAM\/TSP patients"],"prefix":"10.1007","volume":"32","author":[{"given":"Samuel","family":"Brancazio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"issue":"Pt 9","key":"1333_CR1","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1093\/brain\/awt183","volume":"136","author":"H Ando","year":"2013","unstructured":"Ando H, Sato T, Tomaru U, Yoshida M, Utsunomiya A, Yamauchi J, Araya N, Yagishita N, Coler-Reilly A, Shimizu Y, Yudoh K, Hasegawa Y, Nishioka K, Nakajima T, Jacobson S, Yamano Y (2013) Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy. Brain 136(Pt 9):2876\u20132887. https:\/\/doi.org\/10.1093\/brain\/awt183","journal-title":"Brain"},{"issue":"9","key":"1333_CR2","doi-asserted-by":"publisher","first-page":"e42123","DOI":"10.1371\/journal.pone.0042123","volume":"7","author":"TH Araujo","year":"2012","unstructured":"Araujo TH, Souza-Brito LI, Libin P, Deforche K, Edwards D, de Albuquerque-Junior AE, Vandamme AM, Galvao-Castro B, Alcantara LC (2012) A public HTLV-1 molecular epidemiology database for sequence management and data mining. PLoS One. 7(9):e42123. https:\/\/doi.org\/10.1371\/journal.pone.0042123","journal-title":"PLoS One."},{"issue":"1","key":"1333_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1212\/CPJ.0000000000000832","volume":"11","author":"A Araujo","year":"2021","unstructured":"Araujo A, Bangham CRM, Casseb J, Gotuzzo E, Jacobson S, Martin F, Penalva de Oliveira A, Puccioni-Sohler M, Taylor GP, Yamano Y (2021) Management of HAM\/TSP: systematic review and consensus-based recommendations. Neurol Clin Pract. 11(1):49\u201356. https:\/\/doi.org\/10.1212\/CPJ.0000000000000832","journal-title":"Neurol Clin Pract."},{"issue":"Pt 5","key":"1333_CR4","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1099\/vir.0.80766-0","volume":"86","author":"B Asquith","year":"2005","unstructured":"Asquith B, Mosley AJ, Barfield A, Marshall SEF, Heaps A, Goon P, Hanon E, Tanaka Y, Taylor GP, Bangham CRM (2005) A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load. J Gen Virol 86(Pt 5):1515\u20131523. https:\/\/doi.org\/10.1099\/vir.0.80766-0","journal-title":"J Gen Virol"},{"issue":"5","key":"1333_CR5","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1073\/pnas.95.5.2452","volume":"95","author":"N Azimi","year":"1998","unstructured":"Azimi N, Brown K, Bamford RN, Tagaya Y, Siebenlist U, Waldmann TA (1998) Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. Proc Natl Acad Sci U S A 95(5):2452\u20132457. https:\/\/doi.org\/10.1073\/pnas.95.5.2452","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"1333_CR6","doi-asserted-by":"publisher","first-page":"14559","DOI":"10.1073\/pnas.251540598","volume":"98","author":"N Azimi","year":"2001","unstructured":"Azimi N, Nagai M, Jacobson S, Waldmann TA (2001) IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM\/TSP patients. Proc Natl Acad Sci U S A 98(25):14559\u201314564. https:\/\/doi.org\/10.1073\/pnas.251540598","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1333_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1146\/annurev-immunol-042617-053222","volume":"36","author":"CRM Bangham","year":"2018","unstructured":"Bangham CRM (2018) Human T cell leukemia virus type 1: persistence and pathogenesis. Annu Rev Immunol 36:43\u201371","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"1333_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/crispr.2021.0113","volume":"5","author":"D Conant","year":"2022","unstructured":"Conant D, Hsiau T, Rossi N, Oki J, Maures T, Waite K, Yang J, Joshi S, Kelso R, Holden K, Enzmann BL, Stoner R (2022) Inference of CRISPR edits from Sanger trace data. CRISPR J 5(1):123\u2013130. https:\/\/doi.org\/10.1089\/crispr.2021.0113","journal-title":"CRISPR J"},{"issue":"W1","key":"1333_CR9","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gky354","volume":"46","author":"JP Concordet","year":"2018","unstructured":"Concordet JP, Haeussler M (2018) CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens. Nucleic Acids Res 46(W1):W242\u2013W245. https:\/\/doi.org\/10.1093\/nar\/gky354","journal-title":"Nucleic Acids Res"},{"key":"1333_CR10","doi-asserted-by":"publisher","first-page":"1306416","DOI":"10.3389\/fmicb.2023.1306416","volume":"14","author":"MS Cunha","year":"2023","unstructured":"Cunha MS, Zhang W, Mansky LM, Mendon\u00e7a LM (2023) Editorial: HTLV-1: addressing unmet research needs, volume II. Front Microbiol 14:1306416","journal-title":"Front Microbiol"},{"key":"1333_CR11","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1093\/brain\/awad229","volume":"146","author":"NWS Davies","year":"2023","unstructured":"Davies NWS, Taylor GP (2023) Targeted immunotherapy for HTLV-1-associated myelopathy: a step in the right direction. Brain J Neurol 146:3114\u20133116","journal-title":"Brain J Neurol"},{"issue":"66","key":"1333_CR12","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1590\/S1678-9946202466048","volume":"26","author":"W Domingues","year":"2024","unstructured":"Domingues W, Folgosi V\u00c2, Sanabani SS, Leite Junior PD, Assone T, Casseb J (2024) Novel approaches for HTLV-1 therapy: innovative applications of CRISPR-Cas9. Rev Inst Med Trop Sao Paulo 26(66):e48. https:\/\/doi.org\/10.1590\/S1678-9946202466048","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"1333_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12977-019-0499-5","volume":"16","author":"Y Enose-Akahata","year":"2019","unstructured":"Enose-Akahata Y, Jacobson S (2019) Immunovirological markers in HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP). Retrovirology 16:35","journal-title":"Retrovirology"},{"key":"1333_CR14","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3389\/fmicb.2017.02563","volume":"8","author":"Y Enose-Akahata","year":"2017","unstructured":"Enose-Akahata Y, Vellucci A, Jacobson S (2017) Role of HTLV-1 Tax and HBZ in the pathogenesis of HAM\/TSP. Front Microbiol 8:2563","journal-title":"Front Microbiol"},{"key":"1333_CR15","first-page":"721","volume":"13","author":"T Fernandez","year":"2024","unstructured":"Fernandez T, Marconi C, Monta\u00f1o-Castell\u00f3n I, Deminco F, Brites C (2024) A systematical review on ART use in HTLV infection: clinical, virological, and immunological outcomes. Pathogens (Basel, Switzerland) 13:721","journal-title":"Pathogens (Basel, Switzerland)"},{"issue":"5","key":"1333_CR16","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1086\/315897","volume":"182","author":"Y Furukawa","year":"2000","unstructured":"Furukawa Y, Yamashita M, Usuku K, Izumo S, Nakagawa M, Osame M (2000) Phylogenetic subgroups of human T cell lymphotropic virus (HTLV) type I in the tax gene and their association with different risks for HTLV-I-associated myelopathy\/tropical spastic paraparesis. J Infect Dis 182(5):1343\u20131349. https:\/\/doi.org\/10.1086\/315897","journal-title":"J Infect Dis"},{"key":"1333_CR17","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1128\/jvi.66.4.2288-2295.1992","volume":"66","author":"A Gessain","year":"1992","unstructured":"Gessain A, Gallo RC, Franchini G (1992) Low degree of human T-cell leukemia\/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations. J Virol 66:2288\u20132295","journal-title":"J Virol"},{"issue":"7","key":"1333_CR18","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/jmv.22087","volume":"83","author":"MF Grassi","year":"2011","unstructured":"Grassi MF, Olavarria VN, KruschewskyRde A, Mascarenhas RE, Dourado I, Correia LC, de Castro-Costa CM, Galv\u00e3o-Castro B (2011) Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) patients according to new diagnostic criteria of HAM\/TSP. J Med Virol 83(7):1269\u20131274. https:\/\/doi.org\/10.1002\/jmv.22087","journal-title":"J Med Virol"},{"key":"1333_CR19","doi-asserted-by":"publisher","unstructured":"Hashikura Y, Izaki M, Umeki K, Azeta M, Kawano K, Hasegawa H, Saito M, Umekita K (2025) Targeting the gene encoding human T-cell leukemia virus type 1 basic zip factor via CRISPR\/Cas9 potentially mitigates viral infection. PREPRINT (Version 1) available at Research Square. https:\/\/doi.org\/10.21203\/rs.3.rs-6562052\/v1","DOI":"10.21203\/rs.3.rs-6562052\/v1"},{"key":"1333_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1440-1789.2010.01135.x","volume":"30","author":"S Izumo","year":"2010","unstructured":"Izumo S (2010) Neuropathology of HTLV-1-associated myelopathy (HAM\/TSP): the 50th anniversary of Japanese Society of Neuropathology. Neuropathol off J Jpn Soc Neuropathol 30:480\u2013485","journal-title":"Neuropathol off J Jpn Soc Neuropathol"},{"issue":"6298","key":"1333_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/348245a0","volume":"348","author":"S Jacobson","year":"1990","unstructured":"Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S (1990) Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 348(6298):245\u2013248. https:\/\/doi.org\/10.1038\/348245a0","journal-title":"Nature"},{"issue":"3","key":"1333_CR22","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.celrep.2019.09.016","volume":"29","author":"H Katsuya","year":"2019","unstructured":"Katsuya H, Islam S, Tan BJY, Ito J, Miyazato P, Matsuo M, Inada Y, Iwase SC, Uchiyama Y, Hata H, Sato T, Yagishita N, Araya N, Ueno T, Nosaka K, Tokunaga M, Yamagishi M, Watanabe T, Uchimaru K, Fujisawa JI, Utsunomiya A, Yamano Y, Satou Y (2019) The nature of the HTLV-1 provirus in naturally infected individuals analyzed by the viral DNA-capture-seq approach. Cell Rep 29(3):724-735.e4. https:\/\/doi.org\/10.1016\/j.celrep.2019.09.016","journal-title":"Cell Rep"},{"issue":"1","key":"1333_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0165-5728(94)90060-4","volume":"53","author":"R Kubota","year":"1994","unstructured":"Kubota R, Umehara F, Izumo S, Ijichi S, Matsumuro K, Yashiki S, Fujiyoshi T, Sonoda S, Osame M (1994) HTLV-I proviral DNA amount correlates with infiltrating CD4+ lymphocytes in the spinal cord from patients with HTLV-I-associated myelopathy. J Neuroimmunol 53(1):23\u201329. https:\/\/doi.org\/10.1016\/0165-5728(94)90060-4","journal-title":"J Neuroimmunol"},{"issue":"W1","key":"1333_CR24","doi-asserted-by":"publisher","first-page":"W521","DOI":"10.1093\/nar\/gkae241","volume":"52","author":"F Madeira","year":"2024","unstructured":"Madeira F, Madhusoodanan N, Lee J, Eusebi A, Niewielska A, Tivey ARN, Lopez R, Butcher S (2024) The EMBL-EBI Job Dispatcher sequence analysis tools framework in 2024. Nucleic Acids Res 52(W1):W521\u2013W525. https:\/\/doi.org\/10.1093\/nar\/gkae241","journal-title":"Nucleic Acids Res"},{"issue":"10441","key":"1333_CR25","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/S0140-6736(24)00295-2","volume":"403","author":"GN Maertens","year":"2024","unstructured":"Maertens GN, Purcell DFJ, Rosadas C, Bradshaw D, Biglione M, Taylor GP, Martin F (2024) Why not eliminate HTLV-1 while eliminating HIV-1? Lancet 403(10441):2288\u20132289. https:\/\/doi.org\/10.1016\/S0140-6736(24)00295-2","journal-title":"Lancet"},{"key":"1333_CR26","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1080\/14737175.2023.2272639","volume":"23","author":"B Mashkani","year":"2023","unstructured":"Mashkani B, Jalili Nik M, Rezaee SA, Boostani R (2023) Advances in the treatment of human T-cell lymphotropic virus type-I associated myelopathy. Expert Rev Neurother 23:1233\u20131248","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"1333_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrc2111","volume":"7","author":"M Matsuoka","year":"2007","unstructured":"Matsuoka M, Jeang KT (2007) Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 7(4):270\u2013280. https:\/\/doi.org\/10.1038\/nrc2111","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1333_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1080\/13550280152403272","volume":"7","author":"T Matsuzaki","year":"2001","unstructured":"Matsuzaki T, Nakagawa M, Nagai M, Usuku K, Higuchi I, Arimura K, Kubota H, Izumo S, Akiba S, Osame M (2001) HTLV-I proviral load correlates with progression of motor disability in HAM\/TSP: analysis of 239 HAM\/TSP patients including 64 patients followed up for 10 years. J Neurovirol 7(3):228\u2013234. https:\/\/doi.org\/10.1080\/13550280152403272","journal-title":"J Neurovirol"},{"key":"1333_CR29","doi-asserted-by":"publisher","first-page":"e1000027","DOI":"10.1371\/journal.ppat.1000027","volume":"4","author":"KN Meekings","year":"2008","unstructured":"Meekings KN, Leipzig J, Bushman FD, Taylor GP, Bangham CRM (2008) HTLV-1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM\/TSP. PLoS Pathog 4:e1000027","journal-title":"PLoS Pathog"},{"key":"1333_CR30","doi-asserted-by":"publisher","first-page":"867478","DOI":"10.3389\/fmed.2022.867478","volume":"9","author":"M Miura","year":"2022","unstructured":"Miura M, Naito T, Saito M (2022) Current perspectives in human T-cell leukemia virus type 1 infection and its associated diseases. Front Med 9:867478","journal-title":"Front Med"},{"issue":"6","key":"1333_CR31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3109\/13550289809114225","volume":"4","author":"M Nagai","year":"1998","unstructured":"Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, Hashiguchi S, Ichinose M, Bangham CR, Izumo S, Osame M (1998) Analysis of HTLV-I proviral load in 202 HAM\/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM\/TSP. J Neurovirol 4(6):586\u2013593. https:\/\/doi.org\/10.3109\/13550289809114225","journal-title":"J Neurovirol"},{"issue":"2","key":"1333_CR32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2018.06.014","volume":"34","author":"M Nakagawa","year":"2018","unstructured":"Nakagawa M, Shaffer AL 3rd, Ceribelli M, Zhang M, Wright G, Huang DW, Xiao W, Powell J, Petrus MN, Yang Y, Phelan JD, Kohlhammer H, Dubois SP, Yoo HM, Bachy E, Webster DE, Yang Y, Xu W, Yu X, Zhao H, Bryant BR, Shimono J, Ishio T, Maeda M, Green PL, Waldmann TA, Staudt LM (2018) Targeting the HTLV-I-regulated BATF3\/IRF4 transcriptional network in adult T cell leukemia\/lymphoma. Cancer Cell 34(2):286-297.e10. https:\/\/doi.org\/10.1016\/j.ccell.2018.06.014","journal-title":"Cancer Cell"},{"key":"1333_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12030492","author":"T Nakamura","year":"2023","unstructured":"Nakamura T (2023) HAM\/TSP pathogenesis: the transmigration activity of HTLV-1-infected T cells into tissues. Pathogens. https:\/\/doi.org\/10.3390\/pathogens12030492","journal-title":"Pathogens"},{"issue":"1","key":"1333_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12977-017-0350-9.PMID:28420387;PMCID:PMC5395872","volume":"14","author":"S Nozuma","year":"2017","unstructured":"Nozuma S, Matsuura E, Kodama D, Tashiro Y, Matsuzaki T, Kubota R, Izumo S, Takashima H (2017) Effects of host restriction factors and the HTLV-1 subtype on susceptibility to HTLV-1-associated myelopathy\/tropical spastic paraparesis. Retrovirology 14(1):26. https:\/\/doi.org\/10.1186\/s12977-017-0350-9.PMID:28420387;PMCID:PMC5395872","journal-title":"Retrovirology"},{"key":"1333_CR35","doi-asserted-by":"publisher","first-page":"580371","DOI":"10.3389\/fcimb.2020.580371","volume":"10","author":"AR Panfil","year":"2020","unstructured":"Panfil AR, Green PL, Yoder KE (2020) CRISPR genome editing applied to the pathogenic retrovirus HTLV-1. Front Cell Infect Microbiol 10:580371","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"1333_CR36","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1016\/j.ymthe.2023.03.014","volume":"31","author":"T Rojo-Romanos","year":"2023","unstructured":"Rojo-Romanos T, Karpinski J, Millen S, Beschorner N, Simon F, Paszkowski-Rogacz M, Lansing F, Schneider PM, Sonntag J, Hauber J, Thoma-Kress AK, Buchholz F (2023) Precise excision of HTLV-1 provirus with a designer-recombinase. Mol Ther 31(7):2266\u20132285. https:\/\/doi.org\/10.1016\/j.ymthe.2023.03.014","journal-title":"Mol Ther"},{"issue":"6","key":"1333_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1742-4690-6-19","volume":"19","author":"M Saito","year":"2009","unstructured":"Saito M, Matsuzaki T, Satou Y, Yasunaga J, Saito K, Arimura K, Matsuoka M, Ohara Y (2009) In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP). Retrovirology 19(6):19. https:\/\/doi.org\/10.1186\/1742-4690-6-19","journal-title":"Retrovirology"},{"issue":"6","key":"1333_CR38","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1007\/s00415-024-12239-x","volume":"271","author":"T Sato","year":"2024","unstructured":"Sato T, Nagai M, Watanabe O, Misu T, Takenouchi N, Ohkubo R, Ishihara S, Tsuboi Y, Katsuno M, Nakagawa M, Matsushita T, Aso Y, Matsuura E, Tokashiki T, Mukaino A, Adachi H, Nakanishi K, Yamaguchi Y, Yamaguchi S, Yamano Y (2024) Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy. J Neurol 271(6):3471\u20133485. https:\/\/doi.org\/10.1007\/s00415-024-12239-x","journal-title":"J Neurol"},{"key":"1333_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12985-021-01488-1","volume":"18","author":"TA Scott","year":"2021","unstructured":"Scott TA, Morris KV (2021) Designer nucleases to treat malignant cancers driven by viral oncogenes. Virol J 18:18","journal-title":"Virol J"},{"issue":"3","key":"1333_CR40","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1084\/jem.20171626","volume":"215","author":"A Seki","year":"2018","unstructured":"Seki A, Rutz S (2018) Optimized RNP transfection for highly efficient CRISPR\/Cas9-mediated gene knockout in primary T cells. J Exp Med 215(3):985\u2013997. https:\/\/doi.org\/10.1084\/jem.20171626","journal-title":"J Exp Med"},{"issue":"15","key":"1333_CR41","doi-asserted-by":"publisher","first-page":"5389","DOI":"10.1073\/pnas.84.15.5389","volume":"84","author":"M Siekevitz","year":"1987","unstructured":"Siekevitz M, Feinberg MB, Holbrook N, Wong-Staal F, Greene WC (1987) Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type I. Proc Natl Acad Sci U S A 84(15):5389\u20135393. https:\/\/doi.org\/10.1073\/pnas.84.15.5389","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 8","key":"1333_CR42","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1099\/vir.0.010199-0","volume":"90","author":"K Suemori","year":"2009","unstructured":"Suemori K, Fujiwara H, Ochi T, Ogawa T, Matsuoka M, Matsumoto T, Mesnard JM, Yasukawa M (2009) HBZ is an immunogenic protein, but not a target antigen for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes. J Gen Virol 90(Pt 8):1806\u20131811. https:\/\/doi.org\/10.1099\/vir.0.010199-0","journal-title":"J Gen Virol"},{"issue":"8","key":"1333_CR43","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/leu.2013.46","volume":"27","author":"A Tanaka","year":"2013","unstructured":"Tanaka A, Takeda S, Kariya R, Matsuda K, Urano E, Okada S, Komano J (2013) A novel therapeutic molecule against HTLV-1 infection targeting provirus. Leukemia 27(8):1621\u20131627. https:\/\/doi.org\/10.1038\/leu.2013.46","journal-title":"Leukemia"},{"issue":"4","key":"1333_CR44","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S1473-3099(07)70081-6","volume":"7","author":"K Verdonck","year":"2007","unstructured":"Verdonck K, Gonz\u00e1lez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E (2007) Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 7(4):266\u2013281. https:\/\/doi.org\/10.1016\/S1473-3099(07)70081-6","journal-title":"Lancet Infect Dis"},{"key":"1333_CR45","unstructured":"WHO (2021) Human T-lymphotropic virus type 1: technical report. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO"},{"key":"1333_CR46","doi-asserted-by":"publisher","unstructured":"Wilkie T, Panfil AR (2022) CRISPR targeting the integrated HTLV-1 virus. In: Yun YH, Yoder KE (eds) Biotechnologies for Gene Therapy. Springer, Cham. https:\/\/doi.org\/10.1007\/978-3-030-93333-3_6","DOI":"10.1007\/978-3-030-93333-3_6"},{"issue":"3","key":"1333_CR47","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fmicb.2012.00247","volume":"9","author":"T Zhao","year":"2012","unstructured":"Zhao T, Matsuoka M (2012) HBZ and its roles in HTLV-1 oncogenesis. Front Microbiol 9(3):247. https:\/\/doi.org\/10.3389\/fmicb.2012.00247","journal-title":"Front Microbiol"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-026-01333-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13365-026-01333-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-026-01333-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:35:07Z","timestamp":1791297307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13365-026-01333-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1333"],"URL":"https:\/\/doi.org\/10.1007\/s13365-026-01333-7","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"41"}}